© 2002 Canadian Medical Association or its licensors Complaints: (1) A reviewer calls to say he will never review another paper for CMAJ because we accepted a paper he had urged us to reject in view of the authors’ undisclosed and close relationship with a pharmaceutical company. (2) A letter writer complains that we edited her letter so severely that the main point was utterly lost. (3) An aut...

Through implementation of its 2000 pharmaceutical reform, the South Korean government expected to reduce the cost of medications and improve service levels, medical appropriateness of care, and drug effectiveness. However, despite the reform's lofty goals, unintended consequences have distorted the supply of medical services and spending. These consequences have included increasing the use of u...

opening the market early for consumers and for funding the expensive lawsuit. Yet Cobalt, which had agreed to delay consumer access to the generic brand by abandoning its effort to knock out what proved to be a patent that never should have been issued in the first place, was able to “double-dip.” Cobalt was able to keep the money it was paid by the brand-name drug company to abandon the patent...